http://www.pharmexec.com/pharmexec/HomepageEurope/Article/list/48301 The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose of news and features from the world of pharma business and marketing. 2013-05-21T11:23:50Z http://www.pharmexec.com/pharmexec/Europe+Features/A-New-Approach-to-Managing-Safety-Information-in-C/ArticleStandard/Article/detail/626961?contextCategoryId=48301&ref=25 Clinical trials are conducted to prove the efficacy and safety of drugs, so why, Michael Reynolds asks, is so much emphasis is still centred just on efficacy? 2009-09-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626961null HTML http://www.pharmexec.com/pharmexec/Europe/The-power-of-medical-animation/ArticleStandard/Article/detail/621867?contextCategoryId=48301&ref=25 The mechanism of action (MOA) animation is becoming an increasingly popular way to convey important information about a drug, but pharma companies are being slow to realise its potential. Faiz Kermani reports. 2009-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352009/621867null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Need-a-new-non-executive-director/ArticleStandard/Article/detail/621864?contextCategoryId=48301&ref=25 Nick Stephens, CEO of RSA, talks to Pharm Exec Europe about how his company's new register aims to widen the choice of — and choices open to — non-executive directors in the life sciences industry. 2009-08-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352009/621864null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Patent-litigation-insurance-a-win-win-situation/ArticleStandard/Article/detail/621865?contextCategoryId=48301&ref=25 James Blick explains how patent litigation insurance has evolved into a valid — and potentially vital — option for pharmaceutical companies. 2009-08-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352009/621865null HTML http://www.pharmexec.com/pharmexec/Europe/Sweden-takes-the-reins/ArticleStandard/Article/detail/619739?contextCategoryId=48301&ref=25 The presence of a high-flying Obama administration insider at the upcoming Swedish life sciences summit is just one indication of the seriousness with which the country taking its EU presidency. 2009-08-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619739null HTML http://www.pharmexec.com/pharmexec/Europe/Integrating-EU-and-US-regulation/ArticleStandard/Article/detail/619610?contextCategoryId=48301&ref=25 Frost & Sullivan's recently released report — Drug Approval Process in Europe: An Outlook — advocates the integration of the EU and US drug approval processes. 2009-08-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619610/Findlay1_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619610null HTML http://www.pharmexec.com/pharmexec/Europe/Profile-Erin-Gainer/ArticleStandard/Article/detail/619613?contextCategoryId=48301&ref=25 Pharm Exec Europe talks to Dr Erin Gainer, newly-appointed CEO of HRA Pharma, about socially conscious projects, emergency contraception and her peripatetic past in public health and academia. 2009-08-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619613null HTML http://www.pharmexec.com/pharmexec/Europe/Key-Account-Management-always-read-the-label/ArticleStandard/Article/detail/619399?contextCategoryId=48301&ref=25 Dr Brian D. Smith traces the origins of key account management and how it applies in pharmaceutical markets. 2009-08-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619399null HTML http://www.pharmexec.com/pharmexec/Europe/Recession-Proof-Companies-Part-2-Norgine/ArticleStandard/Article/detail/619403?contextCategoryId=48301&ref=25 With 22 consecutive years of European growth under its belt, Norgine is still going from strength to strength. CEO Peter Stein talks to Pharm Exec Europe about the secret of its success. 2009-08-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619403null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Belgiums-statin-stalemate/ArticleStandard/Article/detail/616342?contextCategoryId=48301&ref=25 Reflector reports on how Belgium's best intentions have backfired on its generics manufacturers. 2009-08-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/616342null HTML http://www.pharmexec.com/pharmexec/Europe/Recession-proof-companiesbr--Part-I-Galapagos/ArticleStandard/Article/detail/614388?contextCategoryId=48301&ref=25 Galapagos CEO Onno van de Stolpe talks to Pharm Exec Europe about his 10-year run at the head of the company, a highly successful tenure that shows no sign of slowing down. 2009-08-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/614388null HTML http://www.pharmexec.com/pharmexec/Europe/Why-pharma-should-embrace-multi-level-competition/ArticleStandard/Article/detail/614420?contextCategoryId=48301&ref=25 Increasingly, pharma companies are expanding from brand vs brand to battle at the franchise, portfolio and corporate levels. Stan Bernard explains how this multi-level competition approach can help your company gain competitive advantage. 2009-08-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/614420null HTML http://www.pharmexec.com/pharmexec/Europe/The-antitrust-report-a-legal-perspective/ArticleStandard/Article/detail/612917?contextCategoryId=48301&ref=25 John Cassels of the Competition and EU Regulatory Group at Field Fisher Waterhouse sees the threat of litigation receding in the light of the EC Competition Commission's final report on the pharma sector. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612917null HTML http://www.pharmexec.com/pharmexec/Europe/Does-Big-Pharma-still-exist/ArticleStandard/Article/detail/612921?contextCategoryId=48301&ref=25 Jacky Law sees Roche's recent departure from PhRMA and ABPI as clear evidence that the Big Pharma model is breaking up. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612921null HTML http://www.pharmexec.com/pharmexec/Europe/A-quick-guide-to-EUs-new-pharmacovigilance-package/ArticleStandard/Article/detail/612918?contextCategoryId=48301&ref=25 Deirde McCarthy explains how you can achieve a streamlined and harmonised approach to adopting the EU's new pharmacovigilance guidelines. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612918null HTML http://www.pharmexec.com/pharmexec/Europe/The-EC-antitrust-report-results-are-in-Time-to-pop/ArticleStandard/Article/detail/612916?contextCategoryId=48301&ref=25 The climax of the antitrust investigation instigated with all guns blazing by EC commissioner Neelie Kroes last year has been a whimper, not a bang. Reflector reports. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612916null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Nycomed-licensing-for-long-term-success/ArticleStandard/Article/detail/610864?contextCategoryId=48301&ref=25 Gerhard Symons asks Dr Carlos de Sousa, Vice President Licensing at Nycomed (Zurich) about the firm's in-licensing activities, and what differentiates it from its mid-tier and Big Pharma competitors. 2009-07-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/610864null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Keeping-up-with-KOLs/ArticleStandard/Article/detail/611030?contextCategoryId=48301&ref=25 Dr Brian D. Smith looks at the origins and future of key opinion leadership. 2009-07-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/611030null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Novartis-Why-we-cant-give-free-flu-vaccine-to-poor/ArticleStandard/Article/detail/610863?contextCategoryId=48301&ref=25 Novartis' 'Rethinking Influenza' meeting earlier this month was understandably hijacked by issues surrounding swine flu, one of the most pertinent being the free supply of vaccines to the world's poorest nations. So why, on this issue, is Novartis not playing ball? 2009-07-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/610863null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Big-Pharma-isnt-dead-but-long-live-small-pharma/ArticleStandard/Article/detail/610857?contextCategoryId=48301&ref=25 As the major companies grapple with various crises from patent expirations to regulatory clampdowns, Reflector looks at how small pharma is coming into its own. 2009-07-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/610857null HTML http://www.pharmexec.com/pharmexec/Europe/Knock-em-dead-with-your-website-press-centre/ArticleStandard/Article/detail/603135?contextCategoryId=48301&ref=25 Tired of getting your press releases ignored? Joe Dysart shows you how, by tailoring your communications activities to Web 2.0, to court the media in ways that'll make you stand out. 2009-06-16T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/603135null HTML http://www.pharmexec.com/pharmexec/Europe/Opportunities-in-Vietnam/ArticleStandard/Article/detail/602440?contextCategoryId=48301&ref=25 Jane Wan explains why 'the land of the ascending dragon' is one emerging pharma market that shouldn't be ignored. 2009-06-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/602440null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Reading-the-risk-radar/ArticleStandard/Article/detail/601616?contextCategoryId=48301&ref=25 Following the publication of an Ernst & Young report highlighting the 10 biggest business risks facing life science companies, Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a 'risk radar' to your organisation. 2009-06-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232009/601616null HTML http://www.pharmexec.com/pharmexec/Europe/Pfizer-completes-European-debt-offering/ArticleStandard/Article/detail/601617?contextCategoryId=48301&ref=25 4 June 2009 2009-06-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232009/601617null HTML http://www.pharmexec.com/pharmexec/Web+Exclusives/Belgian-innovation-truffles-or-waffle/ArticleStandard/Article/detail/600036?contextCategoryId=48301&ref=25 Gerhard Symons takes the Eurostar to Belgium to visit some of the leading biotechnology firms in the Bruges-Ghent-Leuven axis in the Flanders region, and unearths the origins of this fertile soil. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600036null HTML http://www.pharmexec.com/pharmexec/Web+Exclusives/Only-the-bad-times-are-good-for-pharma/ArticleStandard/Article/detail/600039?contextCategoryId=48301&ref=25 Jacky Law looks at why the pharma industry has to wait for a global pandemic to be seen in a good light. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600039null HTML http://www.pharmexec.com/pharmexec/Europe+Features/What-business-can-learn-from-the-military/ArticleStandard/Article/detail/600053?contextCategoryId=48301&ref=25 Chris Hart of McKinney Rogers relates how the military's experience of leadership can hold lessons that benefit pharmaceutical CEOs today. Having seen service in Bosnia and Northern Ireland, he is now a UK Partner of global business performance consultancy McKinney Rogers. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600053null HTML